<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Risk-adapted treatment of newly diagnosed Hodgkin lymphoma in children and adolescents</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Risk-adapted treatment of newly diagnosed Hodgkin lymphoma in children and adolescents</h1>
<div class="graphic"><div class="figure"><div class="ttl">Risk-adapted treatment of newly diagnosed Hodgkin lymphoma in children and adolescents</div><div class="cntnt"><table cellspacing="0"><tbody> <tr> <td class="subtitle1_single">Low risk disease*</td> </tr> <tr> <td class="indent1">Four cycles of VAMP (vinblastine, doxorubicin, methotrexate, prednisone) plus LD-IFRT administered after the second cycle of chemotherapy<sup>[1]</sup></td> </tr> <tr> <td class="indent1">Four cycles of COPP (cyclophosphamide, vincristine, procarbazine, prednisone)/ABV (doxorubicin, bleomycin, vinblastine) plus LD-IFRT<sup>[2]</sup></td> </tr> <tr> <td class="indent1">ABVE (doxorubicin, bleomycin, vincristine, etoposide), administered for two to four courses depending on response, followed by LD-IFRT<sup>[3]</sup></td> </tr> <tr> <td class="indent1">OEPA (vincristine, etoposide, prednisone, doxorubicin; for males) or OPPA (vincristine, procarbazine, prednisone, doxorubicin; for females) followed by LD-IFRT, depending upon the initial response to chemotherapy<sup>[4,5]</sup></td> </tr> <tr> <td class="subtitle1_single">Intermediate risk disease*</td> </tr> <tr> <td class="indent1">Six cycles of COPP/ABV plus LD-IFRT<sup>[2]</sup></td> </tr> <tr> <td class="indent1">ABVE-PC (doxorubicin, bleomycin, vincristine, etoposide, prednisone, cyclophosphamide), administered for three to five courses depending upon response, followed by LD-IFRT<sup>[4]</sup></td> </tr> <tr> <td class="indent1">Two cycles of OPPA (for males) or OEPA (for females), followed by two cycles of COPP (for females) or COPDAC (cyclophosphamide, vincristine, prednisone, dacarbazine, for males) plus LD-IFRT<sup>[4-6]</sup></td> </tr> <tr> <td class="subtitle1_single">High risk disease*</td> </tr> <tr> <td class="indent1">ABVE-PC, administered for three to five courses depending upon response, followed by LD-IFRT<sup>[4]</sup></td> </tr> <tr> <td class="indent1">Two cycles of OPPA (for males) or OEPA (for females), followed by two cycles of COPP (for females) or COPDAC (for males) plus LD-IFRT<sup>[4-6]</sup></td> </tr> <tr> <td class="indent1">Two cycles of cytarabine/etoposide, COPP/ABV, and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) plus LD-IFRT<sup>[1]</sup></td> </tr> <tr> <td class="indent1">Four cycles of BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) with subsequent therapy dependent upon response; rapid responders: four cycles of COPP/ABV without IFRT (for females) or two cycles ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) with IFRT (for males); slow responders: four additional cycles of BEACOPP plus IFRT<sup>[7]</sup></td> </tr> </tbody></table></div><div class="graphic_lgnd">This table provides examples of treatment regimens that have been successfully employed in children and adolescents with newly diagnosed Hodgkin lymphoma. A choice among these treatment options is largely based upon physician experience, cancer center preference, and expected toxicities. The determination of preferred therapy for an individual patient should involve a multidisciplinary approach from the time of diagnosis.</div><div class="graphic_footnotes">LD: low dose; IFRT: involved field radiation therapy.<br/>* For definition refer to UpToDate topics on Hodgkin lymphoma in children and adolescents.</div><div class="graphic_reference">References:<br/><ol>
<li>Donaldson SS, Link MP, Weinstein HJ, et al. Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease. J Clin Oncol 2007; 25:332.</li>
<li>Nachman JB, Sposto R, Herzog P, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 2002; 20:3765.</li>
<li>Tebbi CK, Mendenhall N, London WB, et al. Treatment of stage I, IIA, IIIA1 pediatric Hodgkin disease with doxorubicin, bleomycin, vincristine and etoposide (DBVE) and radiation: a Pediatric Oncology Group (POG) study. Pediatr Blood Cancer 2006; 46:198.</li>
<li>Friedman DL, Chen L, Wolden S, et al. Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031. J Clin Oncol 2014; 32:3651.</li>
<li>Dörffel W, Rühl U, Lüders H, et al. Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: Final results of the multinational trial GPOH-HD 95. J Clin Oncol 2013; 31:1562.</li>
<li>Mauz-Körholz C, Hasenclever D, Dörffel W, et al. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol 2010; 28:3680.</li>
<li>Kelly KM, Sposto R, Hutchinson R, et al. BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group. Blood 2011; 117:2596.</li></ol></div><div id="graphicVersion">Graphic 85775 Version 5.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
